Track all markets on TradingView
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
Media

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

  • November 15, 2024
  • 5 Views

Bluebird Bio’s Q3 earnings report showed a narrower-than-expected EPS loss but missed sales targets, leading to a JP Morgan downgrade and cash concerns.

Latest Ratings for BLUE

Date Firm Action From To
Mar 2022 Wells Fargo Maintains Equal-Weight
Mar 2022 Morgan Stanley Maintains Underweight
Mar 2022 Barclays Downgrades Equal-Weight Underweight

View More Analyst Ratings for BLUE

View the Latest Analyst Ratings

read more

​ 

​Bluebird Bio’s Q3 earnings report showed a narrower-than-expected EPS loss but missed sales targets, leading to a JP Morgan downgrade and cash concerns.

Latest Ratings for BLUE
DateFirmActionFromTo Mar 2022Wells FargoMaintainsEqual-Weight Mar 2022Morgan StanleyMaintainsUnderweight Mar 2022BarclaysDowngradesEqual-WeightUnderweight
View More Analyst Ratings for BLUE

View the Latest Analyst Ratings

read more 

Share This Post:

Leave a Reply

Your email address will not be published. Required fields are marked *

This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.